A jab well done: On India’s Human Papillomavirus vaccination programme

What Happened

• Prime Minister Modi formally launched India's nationwide free HPV (Human Papillomavirus) vaccination programme on February 28, 2026, at a ceremony in Ajmer, Rajasthan.
• The programme targets girls aged 9 to 14 years with a single free dose; vaccination is voluntary.
• Two vaccines are being deployed: Gardasil 4 (quadrivalent, imported) and Cervavac (quadrivalent, indigenously developed by the Serum Institute of India).
• All doses are tracked digitally through the U-WIN platform (the government's national immunisation tracking system).
• Each vaccination site is required to have a trained medical officer, anaphylaxis management kits, Cold Chain Points (maintained at 2-8°C), and linkage to 24-hour government health facilities for managing Adverse Events Following Immunisation (AEFI).
• The programme comes amid heightened focus on AEFI surveillance, partly because of historical concerns raised after a 2009-10 HPV trial in Andhra Pradesh and Gujarat, where deaths among trial participants initially generated controversy; an ICMR inquiry concluded those deaths were "most probably unrelated to the vaccine" but recommended stronger AEFI systems and community engagement.
• India carries an estimated 80,000 new cervical cancer cases and 35,000-42,000 deaths per year, contributing approximately one-fifth of the global cervical cancer burden.
• One woman dies of cervical cancer every 8 minutes in India.

Static Topic Bridges

Human Papillomavirus (HPV), Cervical Cancer, and Vaccine Science

Human Papillomavirus is a group of over 200 related viruses transmitted through skin-to-skin and sexual contact. Persistent infection with high-risk strains — particularly HPV 16 and HPV 18 — is responsible for approximately 70% of all cervical cancers globally. Lower-risk strains HPV 6 and HPV 11 cause genital warts.

HPV vaccines are prophylactic (preventive, not therapeutic): they prime the immune system to generate antibodies before exposure to the virus, thereby preventing infection and subsequent oncogenic (cancer-causing) transformation of cervical cells. They do not treat existing infections.

Key vaccine types available in India: - Bivalent (Cervarix): Protects against HPV 16 and 18 - Quadrivalent (Gardasil 4 / Cervavac): Protects against HPV 6, 11, 16, and 18 - Nonavalent (Gardasil 9): Protects against 9 HPV strains (not yet deployed in India's national programme)

Cervavac, developed by the Serum Institute of India with support from the Department of Biotechnology, was launched in September 2022 and is India's first indigenous HPV vaccine. Its development reduces import dependence and significantly lowers the cost compared to imported alternatives.

Adverse Events Following Immunisation (AEFI): Surveillance Systems and Regulatory Framework

Adverse Events Following Immunisation (AEFI) refers to any untoward medical occurrence that follows immunisation and does not necessarily have a causal relationship with the vaccine. AEFI can be: - Vaccine product-related: Inherent properties of the vaccine causing reaction - Vaccine quality defect-related: Manufacturing defects - Immunisation error-related: Improper handling, storage, or administration - Immunisation anxiety-related: Stress response, not caused by vaccine (e.g., fainting) - Coincidental: Unrelated events occurring after vaccination

India's AEFI surveillance is governed by the National AEFI Committee (under the Ministry of Health and Family Welfare), which classifies, investigates, and reports on adverse events. State-level AEFI committees handle field-level investigations. The system follows WHO guidelines on causality assessment.

For the HPV programme specifically, sites must maintain anaphylaxis kits (adrenaline, corticosteroids), observe vaccinees for at least 30 minutes post-injection, and report any adverse events to the district and state health machinery within 24 hours for serious events.

The 2009-10 controversy around HPV trials in India — where seven deaths occurred among trial participants — illustrates the reputational risks when AEFI monitoring is inadequate or perceived to be inadequate. Although investigations found the deaths were coincidental (not vaccine-related), the public controversy led to the suspension of the trials and shaped the more rigorous AEFI infrastructure now mandated for the 2026 national programme.

Universal Immunisation Programme (UIP) and India's Vaccine Policy Architecture

India's Universal Immunisation Programme (UIP), launched in 1985, is one of the largest public health immunisation programmes in the world. It provides free vaccines against 12 preventable diseases (including polio, measles, hepatitis B, rotavirus, pneumococcal disease, and others) to all children and pregnant women. The UIP is a key instrument of India's National Health Mission (NHM).

The HPV vaccination programme is initially being conducted as a special campaign (not yet fully integrated as a routine UIP schedule component) and is tracked through U-WIN — the government's digital immunisation registry that replaced the older paper-based system. U-WIN allows real-time monitoring of coverage, dose scheduling, and adverse event tracking.

India's vaccine policy has evolved significantly: - The Drugs and Cosmetics Act, 1940 and its Rules govern vaccine approvals through CDSCO (Central Drugs Standard Control Organisation) - The National Vaccine Policy (2011) provides the framework for vaccine introduction into the national programme - The National Technical Advisory Group on Immunisation (NTAGI) makes evidence-based recommendations on new vaccine introductions

WHO's Global Strategy for Cervical Cancer Elimination (90-70-90 Targets)

In 2020, the World Health Organization launched a global strategy to eliminate cervical cancer as a public health problem by the end of this century. Elimination is defined as an incidence rate of below 4 per 100,000 women per year (currently India's rate is far above this threshold).

The strategy rests on the 90-70-90 targets, to be achieved by 2030: - 90% of girls fully vaccinated with the HPV vaccine by age 15 - 70% of women screened with a high-performance test by age 35, and again by age 45 - 90% of women identified with pre-cancer or invasive cancer receiving appropriate treatment

This three-pillar approach recognises that vaccination alone is insufficient — screening (via VIA, Pap smear, or HPV DNA test) and treatment (cryotherapy, LEEP, or surgery for pre-cancer; chemotherapy/radiotherapy for invasive cancer) must accompany vaccine coverage to achieve elimination.

India's current HPV vaccination programme directly addresses the first pillar (vaccination). India's cervical cancer screening infrastructure — particularly in rural areas — remains underdeveloped, representing a significant gap in achieving the full 90-70-90 framework.

Key Facts & Data

• Programme launch: February 28, 2026, by PM Modi, at Ajmer, Rajasthan
• Target group: Girls aged 9-14 years; free of cost; voluntary; single-dose schedule
• Vaccines deployed: Gardasil 4 (quadrivalent, imported) and Cervavac (quadrivalent, indigenous — Serum Institute of India)
• Tracking platform: U-WIN (national digital immunisation registry)
• Eligible girls: Approximately 8 crore
• India's cervical cancer burden: ~80,000 new cases/year; ~35,000-42,000 deaths/year
• Mortality rate: One woman every 8 minutes in India
• HPV strains covered by quadrivalent vaccine: 6, 11, 16, 18
• Global vaccine safety record: Over 500 million doses administered since 2006
• Cervavac development: Serum Institute of India, with Department of Biotechnology support; launched September 2022
• 2009-10 controversy: HPV trial deaths in Andhra Pradesh and Gujarat found coincidental by ICMR; strengthened AEFI norms resulted
• WHO elimination target: Cervical cancer incidence below 4 per 100,000 women
• WHO 90-70-90 targets: Vaccination coverage 90% of girls by age 15; screening 70% of women; treatment 90% of identified cases — all by 2030
• NTAGI: National Technical Advisory Group on Immunisation — recommends vaccine introductions into UIP